Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Basit Öğe Kaydı
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorBasoglu, Tugba
dc.contributor.authorNayir, Erdinc
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorPaydas, Semra
dc.contributor.authorGokmen, Ivo
dc.contributor.authorKarakaya, Serdar
dc.date.accessioned2024-11-07T10:39:36Z
dc.date.available2024-11-07T10:39:36Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractSarcomatoid renal cell carcinoma (sRCC) is a rare variant of renal cell carcinoma (RCC) and is associated with a poor prognosis. We reviewed the outcomes of patients from oncology centers in Turkey. Our aim is to share our real-life experience and to contribute to the literature. The demographic and clinical features, treatment, and survival outcomes of 148 patients with sRCC were analyzed. The median age at the time of diagnosis was 58 years (range: 19-83 years). Most patients (62.8%) had clear-cell histology. Most patients were in the intermediate Memorial Sloan-Kettering Cancer Center (MSKCC) risk group (67.6%) and were stage 4 at the time of diagnosis (63.5%). The most common sites of metastasis were the lung (60.1%), lymph nodes (47.3%), and bone (35.8%). The patients received a median of two lines (range: 0-6) of treatment. The most common side effects were fatigue, hematological side effects, hypertension, and hypothyroidism. The median follow-up was 20.9 months (range: 1-162 months). The median overall survival (OS) was 30.8 months (95% confidence interval: 24.9-36.7 months). In multivariate analysis, high MSKCC scores, sarcomatoid differentiation rates >50%, having stage 4 disease, and having lung metastasis at the time of diagnosis were independent factors for poor prognosis affecting OS. No difference was observed between patients who received tyrosine kinase inhibitor (TKI) as the first or second-line treatments. Similarly, no difference between TKI and immunotherapy as the second-line treatment. In conclusion, sRCC is a rare variant of RCC with a poor prognosis and response to treatment. Larger-scale prospective studies are needed to define an optimal treatment approach for longer survival in this aggressive variant.
dc.identifier.doi10.4149/neo_2022_221004N984
dc.identifier.endpage165
dc.identifier.issn0028-2685
dc.identifier.issue1
dc.identifier.pmid36620878
dc.identifier.scopus2-s2.0-85150311495
dc.identifier.scopusqualityQ2
dc.identifier.startpage158
dc.identifier.urihttps://doi.org/10.4149/neo_2022_221004N984
dc.identifier.urihttps://hdl.handle.net/11480/11070
dc.identifier.volume70
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofNeoplasma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCarcinoma, Renal Cell
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectMiddle Aged
dc.subjectMulticenter Studies as Topic
dc.subjectPrognosis
dc.subjectProtein Kinase Inhibitors
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.subjectprotein kinase inhibitor
dc.subjectadult
dc.subjectaged
dc.subjecthuman
dc.subjectkidney tumor
dc.subjectmiddle aged
dc.subjectmulticenter study (topic)
dc.subjectpathology
dc.subjectprognosis
dc.subjectrenal cell carcinoma
dc.subjectretrospective study
dc.subjecttreatment outcome
dc.subjectvery elderly
dc.subjectyoung adult
dc.titleReal-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study
dc.typeReview Article

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu